Figure 2. Survival curves and mitochondrial biomarkers.
A) There was no difference in survival between the rasagiline, placebo, and historical controls (Log-rank test Chi Squared=0.41, p=0.81). Vertical hash lines indicate withdrawals (dropouts). B) We found no treatment-related difference in the 6 months change in blood biomarkers (JC-1 above, ORAC below) which showed drug-target engagement in our prior study.